Merck of­fers new plat­form to en­hance bio­pro­cess­ing

BioSpectrum (India) - - SUPPLIER NEWS -

Merck is col­lab­o­rat­ing with Gly­coBac LLC to of­fer a

Sf-9 in­sect cell line. Gly­coBac’s de­vel­op­ment of a proven rhab­dovirus-neg­a­tive (RVN) cell line en­ables Merck to of­fer the first Sf-9 plat­form com­bin­ing a rhab­dovirus-free in­sect cell line with a cor­re­spond­ing, chem­i­cally de­fined cell cul­ture medium. This will be the first non­mam­malian cell line in Merck’s cell cul­ture port­fo­lio, al­low­ing cus­tomers world­wide ac­cess to a safer, high-per­form­ing ve­hi­cle for re­com­bi­nant pro­tein ex­pres­sion, Virus-like Par­ti­cle vac­cines and Adeno As­so­ci­ated Virus based gene ther­apy production. The in­sect cell line will pro­vide time and cost sav­ings in an­a­lyt­ics and val­i­da­tion, and speed de­vel­op­ment by cir­cum­vent­ing process steps nor­mally re­quired to prove elim­i­na­tion of rhab­dovirus. In ad­di­tion, Merck’s chem­i­cally de­fined hy­drolysate­free medium ad­dresses con­sis­tency con­cerns while also re­duc­ing over­all vari­abil­ity in growth and pro­duc­tiv­ity. Merck’s in­sect cell line ex­tends the com­pany’s up­stream of­fer­ings for viral vac­cine and gene ther­apy ap­pli­ca­tions, com­ple­ment­ing Merck’s well-known mam­malian CHOZN plat­form. Col­lec­tively, Merck’s up­stream and down­stream solutions now con­sti­tute a ro­bust port­fo­lio for mAb, vac­cine and virus production.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.